Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety

Reuters
07/29
Bausch + Lomb Announces Successful Phase 3 Trial Results for LUMIFY Preservative Free Eye Drops, Matching Original's Efficacy and Safety

Bausch + Lomb Corporation has announced the publication of results from a phase 3 study on LUMIFY® Preservative Free Redness Reliever Eye Drops in the journal Ophthalmology and Therapy. The study evaluated the efficacy and safety of the preservative-free formulation compared to the original LUMIFY eye drops in reducing ocular redness. Conducted with 380 participants, the trial demonstrated that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing redness, with a similar safety profile. The results suggest LUMIFY Preservative Free as a well-tolerated option for individuals with sensitivities to preservatives. Additional information is available on the LUMIFY website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729847370) on July 29, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10